News 22.07.2020 Schlieren (Zurich), Switzerland, July 22, 2020 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has been granted the European patent, EP 3268058, entitled ‘Osteoinductive composites’. This patent covers certain combinations of polymers and granular materials and further expands Kuros’s patent portfolio relating to its...
News 20.07.2020 Zurich-Schlieren, Switzerland, July 20, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced that Allergan, an AbbVie company, has informed Molecular Partners of their intent to withdraw application filings with both the European Medicines Agency (EMA) and the...
News 09.07.2020 Zurich-Schlieren, Switzerland, July 9, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced a collaboration with AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), to support development of the company’s tri-specific...
News 07.07.2020 Zurich-Schlieren, Switzerland, July 7, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known asDARPin® therapeutics, today announced that it has successfully placed 5,528,089 registered shares (the New Shares), corresponding to approximately 25% of the company's currently registered share capital,...
News 03.07.2020 Zurich-Schlieren, Switzerland, July 1, 2020. The shareholders of the company elected today Dr. Daniel L. Vasella, – former CEO and President of NOVARTIS - as new members to the Board of Directors of Topadur Pharma AG. “I am extremely happy with the election of Dr. Vasella to the Board of Directors....